Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Carbone

Showing results (361-370 of 651) with videos related to

Pageof 66
Sort By:
Cold Spring Harbor Perspectives in Medicine|September 28, 2021
Lung Cancer Stem Cells and Their Clinical ImplicationsSamuel P Rowbotham, Mounika U L Goruganthu, Rajeswara R Arasada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1995
Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcomaI F Ciernik, B H Krayenbühl Ciernik, C J Cockerell, et al.
Cancer Research|July 15, 1993
A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cellsM Yanuck, D P Carbone, C D Pendleton, et al.
Ebiomedicine|December 24, 2017
Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung AdenocarcinomaMichael F Sharpnack, Bin Chen, Dvir Aran, et al.
Blood|February 15, 2003
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppressionJoyce E Ohm, Dmitry I Gabrilovich, Gregory D Sempowski, et al.
Clinical Lung Cancer|June 11, 2018
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective StudyMarisa A Bittoni, Ashwini Arunachalam, Haojie Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2012
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trialDavid P Carbone, Keyue Ding, Heinrich Roder, et al.
Journal of Physiology and Biochemistry|November 3, 2025
Inhibition of cancerous properties of triple-negative MDA-MB-436 cells by targeting the K<sup>+</sup> voltage-dependent Kv2.1 channelRita Canella, Anna Terrazzan, Francesca P Carbone, et al.
Cancer|May 1, 1978
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapyJ M Bull, D C Tormey, S H Li, et al.
Cancer Research|May 4, 2005
Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancersNobuhiro Haruki, Keiko S Kawaguchi, Shannon Eichenberger, et al.
Pageof 66

Showing results (361-370 of 651) with videos related to

Sort By:
Pageof 66
Cold Spring Harbor Perspectives in Medicine|September 28, 2021
Lung Cancer Stem Cells and Their Clinical ImplicationsSamuel P Rowbotham, Mounika U L Goruganthu, Rajeswara R Arasada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1995
Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcomaI F Ciernik, B H Krayenbühl Ciernik, C J Cockerell, et al.
Cancer Research|July 15, 1993
A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cellsM Yanuck, D P Carbone, C D Pendleton, et al.
Ebiomedicine|December 24, 2017
Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung AdenocarcinomaMichael F Sharpnack, Bin Chen, Dvir Aran, et al.
Blood|February 15, 2003
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppressionJoyce E Ohm, Dmitry I Gabrilovich, Gregory D Sempowski, et al.
Clinical Lung Cancer|June 11, 2018
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective StudyMarisa A Bittoni, Ashwini Arunachalam, Haojie Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2012
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trialDavid P Carbone, Keyue Ding, Heinrich Roder, et al.
Journal of Physiology and Biochemistry|November 3, 2025
Inhibition of cancerous properties of triple-negative MDA-MB-436 cells by targeting the K<sup>+</sup> voltage-dependent Kv2.1 channelRita Canella, Anna Terrazzan, Francesca P Carbone, et al.
Cancer|May 1, 1978
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapyJ M Bull, D C Tormey, S H Li, et al.
Cancer Research|May 4, 2005
Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancersNobuhiro Haruki, Keiko S Kawaguchi, Shannon Eichenberger, et al.
Pageof 66